Introduction
The blood fibrinolytic system which plays a role in the removal of fibrin from the vascular tree consists of three main components : the pro-enzyme plasminogen, which can be activated by limited proteolysis to plasmin; plasminogen activators which may be of different origin (blood activator, endothelial activator, tissue activator or intrinsic plasminogon activator) and a2-antiplasmin which rapidly neutralizes plasmin. The biochemical and biological properties of plasminogen and of a2-antiplasmin, the main inhibitor or plasmin have been studied in detail (for references see ref. 1) . Much less is however known about the "extrinsic" plasminogen activators which are released into the blood, presumably from the vascular wall.
During the past few years specific molecular interactions between plasminogen activator and fibrin, between plasminogen and fibrin and between plasmin and a2-antiplasmin have been described, on the basis of which a molecular model for the regulation of fibrinolysis in vivo was proposed1)2). In addition it has recently become possible to purify "extrinsic" plasminogen activator in sufficient amounts to study its biological properties in more detail.
Regulation and control of fibrinolysis
The regulation and control of fibrinolysis appears to occur at several levels: release of plasminogen activator from the vascular wall, fibrinassociated activation of plasminogen and inhibition of formed plasmin by a2-antiplasmin.
Release of plasminogen activator.
The mechanisms controlling the release of plasminogen activator from the endothelial cells are virtually unknown. Cash has speculated that plasminogen activator release may be under neurohumoral control3). Higher neurogenic centers or specific peripheral afferent organs might stimulate the release of a plasminogen activator releasing hormone (PARH) with a structure similar to vasopression from the neurohypophyseal region. This PARH would constitute the major pathway for the release of plasminogen activator from the endothelial cells, whereas the catecholamine pathway would only be involved in severely stressful situations3). An alternative pathway for the release of 12: 503 plasminogen activator in vivo involving activated protein C has recently been proposed4). Molecular mechanism of physiological fibrinolysis. Physiological fibrinolysis appears to be regulated by specific molecular interactions between plasminogen activator and fibrin, between plasminogen and fibrin and between plasmin and a2-antiplasmin.
As described in more detail below extrinsic plasminogen activator has a weak affinity for plasminogen in the absence of fibrin (KM=65uM) but a much higher affinity in the presence of fibrin (KM between 0.15 and 1.5uM).
This increased affinity appears to be the result of a "surface assembly" of plasminogen activator and plasminogen on the fibrin surface. In this reaction plasminogen binds to fibrin primarily via specific structures called the "lysine-binding site". Thus one way of regulating fibrinolysis is at the level of plasminogen activation localized at the fibrin surface.
Plasmin is extremely rapidly inactivated by a2-antiplasmin (k1=107 M-1s-1)5);
the half-life of free plasmin in the blood is therefore estimated to be approximately 0.1s. Plasmin with an occupied lysine-binding site is however inactivated 50 times slower by a2-antiplasmin. Reversible blocking of the active site of plasmin with substrate also markedly reduces the rate of inactivation by a2-antiplasmin. From these findings one can extrapolate that plasmin molecules generated on the fibrin surface, which are bound to fibrin through their lysinebinding sites and involved in fibrin degradation, are protected from rapid inactivation by a2-antiplasmin. Plasmin released from the fibrin surface would however be rapidly inactivated by a2-antiplasmin.
Studies on human extrinsic plasminogen activator
The molecular model for the regulation of fibrinolysis described above has important consequences for the development of thrombolytic agents. Indeed, the presently available thrombolytic agents streptokinase and urokinase have no specific affinity for fibrin and therefore activate circulating and fibrin-bound plasminogen relatively indiscriminately. Consequently plasmin formed in circulating blood will initially be neutralized very rapidly by a2-antiplasmin and be lost for thrombolysis.
Once the inhibitor becomes exhausted residual plasmin will degrade several plasma proteins (fibrinogen, factor V, factor VIII, etc.) and cause a serious bleeding tendency. This may explain why treatment with streptokinase or urokinase has only a limited efficacy and is associated with serious, sometimes life-threatening side effects.
From this reasoning it appears that specific thrombolysis will only be possible if the activation process of plasminogen can be localized at and confined to the fibrin surface. According to the present concepts this can only adequately be achieved with the use of an activator which, like the physiological activator, adsorbs to the fibrin surface and becomes active in loco. Such plasminogen activators have been isolated from tissues (human uterus, pig ovaries, pig heart, etc.). The yield of these procedures is however extremely low (to obtain 1mg pure activator 5kg of human uterus is required), so that it is practically impossible to foresee any therapeutic application of such substances. We have found that a stable cell line derived from a human melanoma, produced a large amount of a plasminogen activator which appeared to be very similar or identical to the physiological plasminogen activator6). We have deve- As a preliminary to the study of the thrombolytic properties of tissue plasminogen activator in vivo we have investigated the mechanism of inhibition of this activator in human plasma and its turnover following intravenous injection in rabbits. Our studies on the inhibition of tissue plasminogen activator in human plasma revealed that it is slowly inhibited by a2-antiplasmin (t 1/2=60min) and by a2-macroglobulin (t 1/2=120mm). We found no evidence for the existence of another significant inhibitor in plasma8).
Following intravenous injection of mixtures of 125I-labeled and unlabeled tissue plasminogen activator in rabbits the activator activity disappeared with at 1/2 of 2min. This appeared not to be due to inhibition but to cleaning by the 12: 505 liver9).
In in vitro systems composed of mixtures of purified components as well as in total plasma, this activator appeared to have a much higher specific fibrinolytic activity than urokinase. In particular it appeared to be possible to dissolve blood clots hanging in circulating plasma specifically without causing breakdown of the coagulation system in the plasma; this appeared not to be possible with uroki-nase10).
The thrombolytic effect of tissue plasminogen activator was investigated in rabbits with an experimental pulmonary embolus. From this study it appeared that on a molar basis tissue plasminogen activator has a higher thrombolytic effect than urokinase and that (partial) thrombolysis can be obtained without systemic fibrinolytic activation and breakdown of the hemostasis system11 In summary it appears that recent studies have led to a better insight in the regulation and control of the fibrinolytic system in vivo and to the purification and characterization of a plasminogen activator from human cell cultures, which is most probably identical with the physiological plasminogen activator in the blood. This plasminogen activator has the biochemical and biological properties of a specific thrombolytic agent and appears to be effective in experimental thrombosis in animals. Therefore it seems possible and even probable that eventually extrinsic (tissue type) plasminogen activator might constitute a more selective thrombolytic agent than the presently employed urokinase and streptokinase.
